EP3580355A4 - S100 und isoformen zum nachweis von neurologischen störungen - Google Patents

S100 und isoformen zum nachweis von neurologischen störungen Download PDF

Info

Publication number
EP3580355A4
EP3580355A4 EP18751838.6A EP18751838A EP3580355A4 EP 3580355 A4 EP3580355 A4 EP 3580355A4 EP 18751838 A EP18751838 A EP 18751838A EP 3580355 A4 EP3580355 A4 EP 3580355A4
Authority
EP
European Patent Office
Prior art keywords
isoforms
detection
neurological conditions
neurological
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18751838.6A
Other languages
English (en)
French (fr)
Other versions
EP3580355A2 (de
Inventor
Stephen F. LARNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioregency Inc
Original Assignee
Bioregency Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioregency Inc filed Critical Bioregency Inc
Publication of EP3580355A2 publication Critical patent/EP3580355A2/de
Publication of EP3580355A4 publication Critical patent/EP3580355A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP18751838.6A 2017-02-07 2018-02-07 S100 und isoformen zum nachweis von neurologischen störungen Pending EP3580355A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455787P 2017-02-07 2017-02-07
PCT/US2018/017244 WO2018148294A2 (en) 2017-02-07 2018-02-07 S100β AND ISOFORMS FOR DETECTION OF NEUROLOGICAL CONDITIONS

Publications (2)

Publication Number Publication Date
EP3580355A2 EP3580355A2 (de) 2019-12-18
EP3580355A4 true EP3580355A4 (de) 2020-12-16

Family

ID=63107818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18751838.6A Pending EP3580355A4 (de) 2017-02-07 2018-02-07 S100 und isoformen zum nachweis von neurologischen störungen

Country Status (5)

Country Link
EP (1) EP3580355A4 (de)
JP (2) JP2020507622A (de)
AU (1) AU2018219790A1 (de)
CA (1) CA3052636A1 (de)
WO (1) WO2018148294A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871467A1 (fr) * 2004-06-14 2005-12-16 Genoscreen Soc Par Actions Sim Proteine cog47 et polymorphisme du gene s100 beta
WO2009014342A2 (en) * 2007-07-20 2009-01-29 Young In Frontier Co., Ltd. Markers and kit for diagnosis of alzheimer's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5909447B2 (ja) * 2009-09-14 2016-04-26 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2871467A1 (fr) * 2004-06-14 2005-12-16 Genoscreen Soc Par Actions Sim Proteine cog47 et polymorphisme du gene s100 beta
WO2009014342A2 (en) * 2007-07-20 2009-01-29 Young In Frontier Co., Ltd. Markers and kit for diagnosis of alzheimer's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARATEIRO ANDREIA ET AL: "S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 53, no. 6, 17 July 2015 (2015-07-17), pages 3976 - 3991, XP036249031, ISSN: 0893-7648, [retrieved on 20150717], DOI: 10.1007/S12035-015-9336-6 *
DATABASE Geneseq [online] 23 February 2006 (2006-02-23), "Human Cog47 protein SEQ ID NO:1.", XP055747735, retrieved from EBI accession no. GSP:AEE63197 Database accession no. AEE63197 *
GONCALVES C A ET AL: "Biological and methodological features of the measurement of S100B, a putative marker of brain injury", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 41, no. 10-11, 1 July 2008 (2008-07-01), pages 755 - 763, XP022732684, ISSN: 0009-9120, [retrieved on 20080418], DOI: 10.1016/J.CLINBIOCHEM.2008.04.003 *
HEIZMANN C W ET AL: "S100 proteins: structure, functions and pathology", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 7, 1 May 2002 (2002-05-01), pages d1356 - d1368, XP002394878, ISSN: 1093-9946 *

Also Published As

Publication number Publication date
JP2023017805A (ja) 2023-02-07
CA3052636A1 (en) 2018-08-16
JP2020507622A (ja) 2020-03-12
WO2018148294A2 (en) 2018-08-16
EP3580355A2 (de) 2019-12-18
AU2018219790A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
EP3526202A4 (de) Verbindungen und verfahren für gezielten abbau des androgenrezeptors
EP3673080A4 (de) Antisense-oligomere zur behandlung von leiden und krankheiten
EP3399919A4 (de) System und verfahren zum nachweis von nervenerkrankungen
EP3534985A4 (de) Systeme und verfahren zur behandlung von flüssigkeitsüberlastung
EP3570844A4 (de) Azolopyrimidin zur behandlung von krebsbedingten erkrankungen
EP3337476A4 (de) Verbindungen und verfahren für den gezielten abbau von bromdomänenhaltigen proteinen
EP3417240A4 (de) Frühzeitige benachrichtigung eines nicht-autonomen bereichs
EP3270917A4 (de) Verbindungen und verfahren zum verbesserten abbau von zielproteinen
EP3247708A4 (de) Verbindungen und verfahren für gezielten abbau des androgenrezeptors
EP3618829A4 (de) Chinazolin-pyridin-derivate zur behandlung von krebsbedingten erkrankungen
EP3678681A4 (de) Interleukin-18-varianten und verwendungsverfahren
EP3194014A4 (de) Kopfhörer zur neurostimulation und messung von körperparametern
EP3212137A4 (de) Systeme und verfahren zur behandlung von augenleiden
EP3589319A4 (de) Glycaninteragierende verbindungen und verfahren zur verwendung
EP3634417A4 (de) Chinazolin-pyrazolderivate zur behandlung von krebsbedingten erkrankungen
SG11202104501UA (en) Systems and methods for the treatment of eye conditions
EP3684418A4 (de) Verfahren zur behandlung von cysteaminempfindlichen erkrankungen
EP3638808A4 (de) Detektion gezielter sequenzregionen
EP3727141A4 (de) Verfahren und systeme zur verbesserten sammlung von interstitieller flüssigkeit
EP4022066A4 (de) Verfahren und systeme zur bewertung der risikofaktoren von drogenmissbrauchserkrankungen
EP3445231A4 (de) Systeme und verfahren zur charakterisierung von anfällen
EP3538101A4 (de) Inhibitoren der invasion, anheftung und/oder metastasierung von krebs
EP3809957A4 (de) Systeme und verfahren zur beurteilung der gesundheitssituation oder des gesundheitszustands
EP3374354A4 (de) Benzofuranderivate zur behandlung des zentralen nervensystems (zns) und anderen erkrankungen
EP3319564B8 (de) Ophthalmisches kratzgerät und verfahren zur dessen herstellung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201118

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6883 20180101ALI20201112BHEP

Ipc: C07K 16/18 20060101ALI20201112BHEP

Ipc: C12Q 1/68 20180101AFI20201112BHEP

Ipc: G01N 33/68 20060101ALI20201112BHEP

Ipc: G01N 33/564 20060101ALI20201112BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231124